Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Center LaboratoriesROCO:4123 +1.35%69 Days Payable is 44.67 as of Dec. 2025, which is 17% below its 10-year median of 53.82. GuruFocus rates ROCO:4123 with a GF Score™ of 69/100 and a GF Value™ of NT$43.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Center Laboratories ranks worse than 73.62% on this metric.
The historical rank and industry rank for Center Laboratories's Days Payable or its related term are showing as below:
ROCO:4123'
s Days Payable Range Over the Past 10 Years
Min: 22.33 Med: 53.82 Max: 81.04
Current: 51.77
During the past 13 years, Center Laboratories's highest Days Payable was 81.04. The lowest was 22.33. And the median was 53.82.
ROCO:4123's Days Payable is ranked worse than 73.62% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:4123: 51.77
Center Laboratories's Days Payable
declined
from Dec. 2024 (47.80) to Dec. 2025 (44.67).
It may suggest that Center Laboratoriesaccelerated paying its suppliers.
Center Laboratories Days Payable Related Terms
Center Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Center Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Center Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Center Laboratories's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Center Laboratories (ROCO:4123) has a Days Payable of 44.67 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Center Laboratories and its competitors. This is 17% below median its historical median of 53.82. Over the past decade, Center Laboratories' Days Payable has ranged from 22.33 to 81.04. According to the industry distribution chart, Center Laboratories ranks #681 out of 925 companies in the Drug Manufacturers industry, placing it in the top 73.6%.
Is Center Laboratories' Days Payable too high?
Center Laboratories' current Days Payable of 44.67 is 17% below median its 10-year median of 53.82. Over the past 10 years, this metric has ranged from a low of 22.33 to a high of 81.04. The Drug Manufacturers industry median Days Payable is 90.38. Center Laboratories' value of 44.67 is 50.6% below this industry median. Based on the distribution chart, Center Laboratories ranks #681 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Center Laboratories has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #681 out of 925 companies for Days Payable. This places Center Laboratories in the lower half of its industry. The industry median Days Payable is 90.38. Center Laboratories' value of 44.67 is 50.6% below this benchmark. Historically, Center Laboratories' own Days Payable has ranged from 22.33 to 81.04 over the past decade. While the company's 10-year median is 53.82 vs. the industry median of 90.38, Center Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Center Laboratories's current Days Payable of 44.67 is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current Days Payable is 44.67, which is 17% below median its own 10-year median of 53.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.04, compared to a current price of NT$37.50 — trading 12.9% below its estimated fair value. The current Days Payable is 44.67, which is 17% below median its 10-year median of 53.82 and 50.6% below the Drug Manufacturers industry median of 90.38. Center Laboratories' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current Days Payable is 44.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$37.50 is trading 12.9% below its estimated GF Value™ of NT$43.04.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
Days Payable: 44.67 (17% below median its 10-year median of 53.82)
GF Value™: NT$43.04 vs. price of NT$37.50 (12.9% below fair value)
Industry Position: 50.6% below the Drug Manufacturers median (#681 of 925)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score
Get the complete analysis for ROCO:4123
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
